Research progress of myeloproliferative neoplasms.
10.7534/j.issn.1009-2137.2015.01.053
- Author:
Hai-Ju HE
1
;
Bao-An CHEN
2
Author Information
1. Department of Hematology, Zhongda Hospital, Southeast University Medical School, Nanjing 210009, Jiangsu Province, China.
2. Department of Hematology, Zhongda Hospital, Southeast University Medical School, Nanjing 210009, Jiangsu Province, China. E-mail: cba8888@hotmail.com.
- Publication Type:Journal Article
- MeSH:
Fusion Proteins, bcr-abl;
Humans;
Myeloproliferative Disorders;
Polycythemia Vera;
Primary Myelofibrosis;
Prognosis;
Thrombocythemia, Essential;
World Health Organization
- From:
Journal of Experimental Hematology
2015;23(1):278-284
- CountryChina
- Language:Chinese
-
Abstract:
The classic BCR-ABL negative myeloproliferative neoplasm (MPN) comprise polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). These three disorders are characterized by stem cell-derived clonal myeloproliferation and presence of somatic mutations. The WHO diagnostic criteria for the classic BCR-ABL negative MPN has been revised in the 2008 edition by incorporating new information about their molecular pathogenesis. Robust prognostic system for PMF has already done, and those for PV and ET are under discussion. Treatment with novel drugs is promising, and allo-stem cell transplantation (allo-ASCT) is the only curative treatment for myelofibrosis, however, the patient selection and management before transplant have been discussed for a long time.
